|
|
 |
|
 |
|
|
|
| Key Trends in Offshoring Pharmaceutical R&D: Company strategies, emerging markets and impact on ROI |
| Buy Now $3835 | Buy with Credit Card |
| DOWNLOAD FREE:
Table of Contents | Brochure & Fax-Back Order Form | Press
|
|
|
| Offshoring and outsourcing have become an increasingly critical contributor to pharma and biotech R&D strategies in recent years. They enable companies to focus on core competencies such as drug discovery or technology development whilst contracting out non-core processes to experts, often at lower costs. As offshore investments begin to mature and provide returns on investment, the opportunity to migrate individual components or whole segments of R&D portfolios will continue to rise. ‘Key Trends in Offshoring Pharmaceutical R&D’ is a new report published by Business Insights that evaluates the offshore R&D strategies that can reduce development times and improve productivity, with analysis of a variety of strategic partnerships, academic collaborations, and outsourcing opportunities. This report identifies emerging areas of technological and scientific significance across the globe and examines the offshore strategies and investments of the top 20 pharma and biotech companies across Asia, Australia, Central and Eastern Europe, Latin America and the Far East. This report also provides a financial and managerial valuation of leading companies based on their P/E ratio, return on assets (ROA) and return on investment (ROI) and measures company performance against the healthcare industry, pharmaceutical and biotechnology sectors and leading shares of the S&P500.
Published: March 2009 - Global. |
|
|
|
|
|
|
| |
